Cardiological aspects of prostate cancer treatment
DOI: https://doi.org/10.22591/magyurol.2023.3.drobnizs.114 
Authors:
Drobni Zsófia Dóra dr.1, Fazekas Tamás dr.2,
Becker Dávid dr.1, Nyirády Péter dr.2
1Városmajori Szív- és Érgyógyászati Klinika, Kardiológia Tanszék,
Semmelweis Egyetem, Budapest (tanszékvezető: Becker Dávid dr.)
2Semmelweis Egyetem, Urológiai Klinika és Andrológiai Centrum, Budapest (igazgató: Nyirády Péter dr.)
Summary
Several new therapeutic agents have been recently approved for prostate cancer (PC) treatment, significantly improving patient survival. Currently, the systemic treatment of PC consists of hormone therapy, chemotherapy, immunotherapy, radiopharmaceuticals, and targeted therapy, many of which are associated with cardiovascular complications. In patients with PC, the prevalence of cardiovascular comorbidity is about 30%, and the incidence of cardiovascular mortality is 25-35%. This review provides an overview of systemic PC therapies’ prevalence and possible mechanisms of cardiovascular toxicity, including state-of-the-art anticancer agents. We also present the relevant recommendations of the European Society of Cardiology, published in the summer of 2022, on screening, risk assessment, follow-up, and prevention of the most common cardiac complications.